Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dispenzieri

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
Bone Marrow Transplantation|April 11, 2006
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemiaM A Elliott, A Tefferi, W J Hogan, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Bone Marrow Transplantation|April 11, 2017
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survivalN Tandon, E Muchtar, S Sidana, et al.
Leukemia|March 26, 2004
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myelomaL F Porrata, M A Gertz, S M Geyer, et al.
Leukemia|October 22, 2015
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myelomaG P Kaufman, M A Gertz, A Dispenzieri, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Bone Marrow Transplantation|April 11, 2006
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemiaM A Elliott, A Tefferi, W J Hogan, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Blood Cancer Journal|October 21, 2017
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination SurveyO Landgren, B I Graubard, S Kumar, et al.
Leukemia|August 15, 2015
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myelomaS K Kumar, E Ma, A E Engebretson, et al.
Leukemia|May 24, 2016
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agentsN Majithia, S V Rajkumar, M Q Lacy, et al.
Bone Marrow Transplantation|April 11, 2017
Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survivalN Tandon, E Muchtar, S Sidana, et al.
Leukemia|March 26, 2004
The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myelomaL F Porrata, M A Gertz, S M Geyer, et al.
Leukemia|October 22, 2015
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myelomaG P Kaufman, M A Gertz, A Dispenzieri, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Pageof 16